Close Menu

research consortium

The consortium, recently funded with €750,000, is developing a computational tool for identifying NAFLD patients at high risk of progressing to NASH.

Called CoronaDx, which has a budget of €3 million, aims to facilitate the development of testing systems for use in remote areas with limited infrastructure.

The test could also be used to assess vaccine effectiveness, should a vaccine become available.

A consortium led by the Barcelona-based company recently received €150,000 in EU funding to bring the platform to market.

The effort, called INNO4COV-19, was awarded €6.1 million last month to support the commercialization of new diagnostics.

The effort is one of 23 research projects selected as part of a new, €128 million EU package to combat COVID-19.

Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.

While results are preliminary, the test could potentially be used in lieu of a liver biopsy.

VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.

The firm's EpiSwitch test for blood-based diagnosis of prostate cancer will be evaluated as part of the ongoing PROSTAGRAM trial.